Shares of Biogen (BIIB) and Alexion Pharmaceuticals (ALXN) took a hit Tuesday after their promising new products failed clinical trials. Biogen's experimental drug aimed at treating multiple sclerosis failed a mid-staged trial, prompted investors to sell shares. Biogen stock is a holding of Jim Cramer's Action Alerts PLUS charitable trust. Our Jim Cramer says the so-called 'novel' therapy turned out to be yet another 'disaster in Biogen's history of overpromising and under- delivering.' And, Alexion Pharmaceuticals also said that a medication it was developing aimed to treat muscle weakness, produced lackluster results. Alexion said in a statement the study also missed its 'primary endpoint' and that cases of successful responses to the drug 'missed statistical significance.'
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.